Invion Ltd. · ASX:IVX
Invion — BioCentury-BayHelix East-West Summit 2024
29 slides from Invion's conference presentation, Mar 5, 2024
Slide 1: ASX Announcement: Investor Presentation for East-West Summit
ASX ANNOUNCEMENT INVESTOR PRESENTATION FOR EAST-WEST SUMMIT MELBOURNE (AUSTRALIA) 05 March 2024: Invion Limited (ASX: IVX) (“Invion” or the “Company”) wishes to release the attached presentation, which will be presented by the Company’s Executive Chair and Chief Executive Officer, Thian Chew, at the
Slide 2: Corporate Presentation March 2024
For personal use only CORPORATE PRESENTATION March 2024 ASX: IVX
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Clinical Inflexion Point: PDT for Cancers and Infectious Diseases
CLINICAL INFLEXION POINT PDT FOR TREATMENT OF CANCERS AND INFECTIOUS DISEASES ❑ Clinical stage life-science company using proprietary Photodynamic Therapy (PDT) technology (Photosoft ) to treat a range of cancers and infectious diseases. For personal use only ❑ Focus on unmet medical needs particula
Slide 5: Background and Development Timeframe: Cancer
BACKGROUND AND DEVELOPMENT TIMEFRAME: CANCER PATHWAY TO CLINICAL TRIALS For personal use only Partnership with Peter Mac PoC 2: Complete COVID-19 Lockdowns regression of TNBC Potential in metastatic PoC 3: INV043 cancers significantly improves ICI therapy Photosoft destroys INV043 effective ovarian
Slide 6: The Photosoft Advantage: A Novel Cancer Treatment
THE PHOTOSOFTTM ADVANTAGE A NOVEL CANCER TREATMENT NGPDT (Next-Gen PDT) is a ground-breaking For personal use only technology that overcomes many of the NGPDT is a minimally invasive modality for treating cancer that specifically identifies and shortcomings of early PDT technologies and destroys can
Slide 7: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS ATTRACTIVE THERAPEUTIC PROFILE A. INV043 Activity Against B. A. INV043 Multiple Cancer Activity Cell TypesAgainst INV043 vs Preclinical studies in lead cancer candidate INV043 show: INV043 100 activity Multipleagainst Cancermultiple cancer cell type
Slide 8: Potential to Activate an Immune Response
POTENTIAL TO ACTIVATE AN IMMUNE RESPONSE PROTECTIVE IMMUNITY AND ABSCOPAL EFFECT “PDT has the potential to eliminate metastatic and disseminated tumor cells by promoting antitumor immunity”1 For personal use only ABSCOPAL EFFECT2 PROTECTIVE IMMUNITY NON-IRRADIATED SIDE NON-IRRADIATED SIDE IRRADIATED
Slide 9: Combination with Immune Checkpoint Inhibitors (ICI)
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL • Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers • Despite widespread use of ICIs, the patient response rate can be as low as
Slide 10: Treatment Options: Maximising Flexibility for Clinicians
TREATMENT OPTIONS: MAXIMISING FLEXIBILITY FOR CLINICIANS MULTIPLE PATHWAYS FOR DRUG AND TARGETED LIGHT DELIVERY For personal use only ROUTES OF DRUG ADMINISTRATION LIGHT ADMINISTRATION OPTIONS TOPICAL INTRAVENOUS TOPICALLY (LASER/LED) ENDOSCOPICALLY INTRATUMORAL SUBLINGUAL WITH OPEN SURGERY KEYHOLE
Slide 11: Target Indications and Timeframes
TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS, MULTIPLE INDICATIONS AND FORMULATIONS DISEASE AREA (CALENDAR YEAR) 2H2023 1H2024 2H2024 1H2025 2H2025 >CY26 For personal use only CANCER1 Recruitment and Treatment Non-Melanoma Skin Cancers (Topical)2 Adaptive study design Follow up and mon
Slide 12: Evaluating NMSC Therapies
EVALUATING NMSC THERAPIES1 IVX-PDT – POTENTIAL TO DISPLACE STANDARD OF CARE Skin (NMSC) For personal use only GOOD Metvix/ALA IVX-PDT COSMETIC RESULT Cryosurgery Mohs Surgery Curettage & Electrodesiccation Less Pain/ More Pain/ Discomfort) Discomfort Excisional Surgery POOR FAIR EFFECTIVENESS GOOD 1
Slide 13: Unlocking Hope for Cancer Patients Using PDT
UNLOCKING HOPE FOR CANCER PATIENTS USING PDT ADDRESSING LIMITATIONS OF CONVENTIONAL TREATMENT OPTIONS For personal use only No Resistance Development, A Minimally Invasive treatment allowing for repeated option that preserves both treatments on recurring tumors function and aesthetics without compro
Slide 14: Broad-Spectrum Anti-Microbial Potential
BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL POSSIBILITY FOR SEVERAL ANTIMICROBIAL TREATMENTS – WITHOUT RESISTANCE “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” For personal use only World Health Organisation1 Leading Institutions: Viroclinics conducted virus SARS-CoV-2: O
Slide 15: Agreement to Develop and Fund Photosoft for HPV
AGREEMENT TO DEVELOP AND FUND PHOTOSOFT FOR HPV HPV IS THE MOST COMMON SEXUALLY TRANSMITTED INFECTION GLOBALLY1 In all females, the highest (HPV) prevalence is found in Asian regions2 For personal use only HPV distribution profile in women 2 CHALLENGES IN TREATMENT 57.7% • Viral persistence and recu
Slide 16: Addressing Asian-Centric Diseases
ADDRESSING ASIAN-CENTRIC DISEASES ADDRESSING A GLOBALLY RELEVANT UNMET NEED Asians comprise 6% of clinical trial patients in FDA approved drugs2 For personal use only … yet 60% of the world is Asian UNDER-REPRESENTATION IN MISMATCH WITH GLOBAL INCIDENCE DRUG DEVELOPMENT Ethnic Breakdown of Clinical
Slide 17: Stanford Center for Asian Health Research and Education (CARE)
Stanford Center for Asian Health Research and Education (CARE) • Only medical center among top universities in the US dedicated to enhancing the precision health of Asians globally For personal use only • Rooted in Stanford Medicine’s pioneering precision health approach, we are committed to targete
Slide 18: CARE Precision Asian Health Framework
CARE Precision Asian Health Framework Vision Academic Leader in For personal use only Precision Asian Health Research Education Community Pillars Asian Health Research and Education Platform Summit / Conference Management Infrastructure Research / Education Grant Support Platform Public Policy Initi
Slide 19: Invion
INVION Ajuo asn yeuosiad JO 4
Slide 20: Appendices
For personal use only APPENDICES
Slide 21: Tumour Regression In Vivo
TUMOUR REGRESSION IN VIVO SIGNIFICANT REGRESSION ON MULTIPLE TUMOUR TYPES • INV043 was used to treat implanted T-cell lymphoma, breast and pancreatic cancers in vivo For personal use only • Low dose (0.1mg/kg) administered by intra-tumoral injection and laser light applied after 1.5 hours. Treated t
Slide 22: Peter Mac Combination ICI and INV043 Study
PETER MAC COMBINATION ICI AND INV043 STUDY STUDY DESIGN • The study was conducted by Peter Mac using immune competent anal squamous cell carcinoma (ASCC) in vivo models For personal use only • INV043 was topically applied to 6-8 week old C57BL/6 mice followed 3 hours later with 71 J/cm2 of 660nm lig
Slide 23: Peter Mac Combination ICI and INV043 Study: Findings
PETER MAC COMBINATION ICI AND INV043 STUDY FINDINGS AND IMPLICATIONS • Combination therapy using INV043 with ICIs led to ~80% control of ASCC tumours at study endpoint, compared with ICI therapy alone, which achieved ~12% control. Results were statistically significant For personal use only • Mice u
Slide 24: Non-Melanoma Skin Cancer (NMSC)
NON-MELANOMA SKIN CANCER (NMSC) THE WORLD’S MOST COMMON CANCER : SKIN CANCER4 Australia: Highest skin cancer incidence globally2 Skin (NMSC) For personal use only Melanoma NM S C: I n c i d e n c e r a te s ~1% (2 0 2 0 ) 2 p e r 1 0 0 , 0 0 0 SCC Others 150 114.9 ~19% ~1% 100 64.4 50 16 BCC 1.5 SQU
Slide 25: Phase 1/2 Non-Melanoma Skin Cancer Trial Design
PHASE 1/2 NON-MELANOMA SKIN CANCER TRIAL DESIGN1 ADAPTIVE DESIGN: SAFETY AND TOLERABILITY, DOSE OPTIMISATION, EFFICACY • Increased Optionality: Open label adaptive trial design (3+3 light dose / dose light interval escalation2) enables flexibility in size and timing, with option for repeat treatment
Slide 26: Oral Periodontal Diseases
ORAL PERIODONTAL DISEASES 19% OF GLOBAL ADULTS SUFFER FROM SEVERE PERIODONTAL DISEASES1 Oral periodontal diseases are one of the major public health challenge in South-East Asia – WHO5 For personal use only Increase in Prevalence over decades2 1,087,000,000 “20% of Implant patients suffer from peri-
Slide 27: Invion Dental Kit
INVION DENTAL KIT1 POTENTIAL TO ADDRESS PERIODONTAL NEEDS, EFFICIENT PATH US FDA APPROVAL For personal use only INVION DENTAL RINSE INVION DENTAL DEVICE ➢ Alternatives to antibiotic therapy What Periodontists ➢ Tackling the menace of biofilms ➢ Non-surgical access to deep pockets are looking for ➢ C
Slide 28: Market Overview
1-Year Price and Volume MARKET OVERVIEW $0.005 For personal use only (@ 28 February 2024) Market Cap A$32.1m Clinical-stage life Source: Market Index sciences company developing the Focus PhotosoftTM technology as Top 10 Shareholders % a treatment for a range of diseases including POLAR VENTURES LIM
Slide 29: Experienced Team
EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS THIAN CHEW SCOTT CARPENTER EXECUTIVE CHAIRMAN & CEO PROGRAM DIRECTOR For personal use only • Co-Founder, Chronic Airway Therapeutics • Director Business Development, Starpharma • Advisory Board, Stanford Medicine CARE • Program Manager, AusBiotech • E